mapracorat
Small moleculeexperimental
Mapracorat is an anti-inflammatory drug belonging to the experimental class of selective glucocorticoid receptor agonists (SEGRAs). It is in clinical trials for the topical treatment of atopic dermatitis, inflammation following cataract surgery, and allergic conjunctivitis. Preliminary investigation for the treatment of keratoconjunctivitis sicca has been conducted in cellular models. — Wikipedia
Clinical trial activity
14 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
12
Phase 3
4
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00905450)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1- Mol. weight
- 462.49 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMapracorat ↗
- ChEMBLCHEMBL2103876 ↗
Also known as
- bol 303242-x
- bol-303242-x
- bol-303242-x
- bol-303242-x
- bol-303242-x
- bol303242-x
- mapracorat
- mapracorat
- mapracorat
- mapracorat
- mapracorat
- r-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol
- zk245186
- zk245186
- zk 245186
- zk 245186
- zk 245186
- zk-245186
- zk-245186
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03399526 | Phase 1 | Feb 11, 2013 | Bayer |
| NCT01736462 | Phase 1 | Feb 1, 2013 | Bausch & Lomb |
| NCT01591655 | Phase 3 | Jul 1, 2012 | Bausch & Lomb |
| NCT01591161 | Phase 3 | Jul 1, 2012 | Bausch & Lomb |
| NCT01408511 | Phase 2 | Jul 1, 2011 | Bayer |
| NCT01359787 | Phase 2 | May 1, 2011 | Bayer |
| NCT01407510 | Phase 2 | May 1, 2011 | Bayer |
| NCT01289431 | Phase 2 | Feb 1, 2011 | Bausch & Lomb |
| NCT01298752 | Phase 3 | Feb 1, 2011 | Bausch & Lomb |
| NCT01230125 | Phase 3 | Nov 1, 2010 | Bausch & Lomb |
| NCT01228513 | Phase 2 | Nov 1, 2010 | Bayer |
| NCT01163643 | Phase 2 | Jul 1, 2010 | Bausch & Lomb |
| NCT00944632 | Phase 2 | Jul 1, 2009 | Bayer |
| NCT00905450 | Phase 2 | Jun 1, 2009 | Bausch & Lomb |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch & Lomb | For profit | 8 | 8 | 3 | 2009 |
| Bayer | For profit | 6 | 6 | 2 | 2009 |
2 organizations
Page 1 / 1